CN114539228A - 三嗪类化合物或其可药用盐、异构体、药物组合物和用途 - Google Patents
三嗪类化合物或其可药用盐、异构体、药物组合物和用途 Download PDFInfo
- Publication number
- CN114539228A CN114539228A CN202210247036.4A CN202210247036A CN114539228A CN 114539228 A CN114539228 A CN 114539228A CN 202210247036 A CN202210247036 A CN 202210247036A CN 114539228 A CN114539228 A CN 114539228A
- Authority
- CN
- China
- Prior art keywords
- compound
- pharmaceutically acceptable
- isomer
- acceptable salt
- metabolite
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000003839 salts Chemical class 0.000 title claims abstract description 43
- -1 Triazine compound Chemical class 0.000 title claims abstract description 30
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 15
- 239000002207 metabolite Substances 0.000 claims abstract description 30
- 239000003814 drug Substances 0.000 claims abstract description 22
- 239000000651 prodrug Substances 0.000 claims abstract description 13
- 229940002612 prodrug Drugs 0.000 claims abstract description 13
- 239000012453 solvate Substances 0.000 claims abstract description 13
- 208000035473 Communicable disease Diseases 0.000 claims abstract description 5
- 150000001875 compounds Chemical class 0.000 claims description 79
- 238000006243 chemical reaction Methods 0.000 claims description 22
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 16
- 229910052805 deuterium Inorganic materials 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 9
- 208000015181 infectious disease Diseases 0.000 claims description 7
- 230000003612 virological effect Effects 0.000 claims description 6
- 101000749287 Clitocybe nebularis Clitocypin Proteins 0.000 claims description 4
- 101000767029 Clitocybe nebularis Clitocypin-1 Proteins 0.000 claims description 4
- 229940094664 Cysteine protease inhibitor Drugs 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- 150000003918 triazines Chemical class 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 3
- 230000009471 action Effects 0.000 claims description 2
- 239000003513 alkali Substances 0.000 claims description 2
- 150000004677 hydrates Chemical class 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 17
- 230000000694 effects Effects 0.000 abstract description 11
- 239000003112 inhibitor Substances 0.000 abstract description 11
- 230000002401 inhibitory effect Effects 0.000 abstract description 9
- 150000003384 small molecules Chemical class 0.000 abstract description 7
- 102000005927 Cysteine Proteases Human genes 0.000 abstract description 4
- 108010005843 Cysteine Proteases Proteins 0.000 abstract description 4
- 230000007547 defect Effects 0.000 abstract 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 21
- 238000005160 1H NMR spectroscopy Methods 0.000 description 20
- 230000015572 biosynthetic process Effects 0.000 description 20
- 238000003786 synthesis reaction Methods 0.000 description 20
- 239000000243 solution Substances 0.000 description 18
- 241000711573 Coronaviridae Species 0.000 description 17
- 241000700605 Viruses Species 0.000 description 16
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 15
- 229940126246 S-217622 Drugs 0.000 description 14
- 101800000504 3C-like protease Proteins 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 239000000203 mixture Substances 0.000 description 12
- 241001678559 COVID-19 virus Species 0.000 description 11
- 239000002994 raw material Substances 0.000 description 11
- 239000002253 acid Substances 0.000 description 10
- 238000001308 synthesis method Methods 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 9
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 9
- 239000002585 base Substances 0.000 description 9
- 238000001914 filtration Methods 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 238000004440 column chromatography Methods 0.000 description 7
- 238000001035 drying Methods 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 241000709661 Enterovirus Species 0.000 description 6
- 231100000135 cytotoxicity Toxicity 0.000 description 6
- 230000003013 cytotoxicity Effects 0.000 description 6
- 239000012065 filter cake Substances 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical class Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 239000007832 Na2SO4 Substances 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 229910052938 sodium sulfate Inorganic materials 0.000 description 5
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
- TZKBVRDEOITLRB-UHFFFAOYSA-N 4-methyl-n-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-3-[2-(1h-pyrazolo[3,4-b]pyridin-5-yl)ethynyl]benzamide Chemical compound C1CN(C)CCN1CC(C(=C1)C(F)(F)F)=CC=C1NC(=O)C1=CC=C(C)C(C#CC=2C=C3C=NNC3=NC=2)=C1 TZKBVRDEOITLRB-UHFFFAOYSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 208000025721 COVID-19 Diseases 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 239000004365 Protease Substances 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 238000000967 suction filtration Methods 0.000 description 4
- 241000712461 unidentified influenza virus Species 0.000 description 4
- 230000009385 viral infection Effects 0.000 description 4
- LJIOTBMDLVHTBO-CUYJMHBOSA-N (2s)-2-amino-n-[(1r,2r)-1-cyano-2-[4-[4-(4-methylpiperazin-1-yl)sulfonylphenyl]phenyl]cyclopropyl]butanamide Chemical compound CC[C@H](N)C(=O)N[C@]1(C#N)C[C@@H]1C1=CC=C(C=2C=CC(=CC=2)S(=O)(=O)N2CCN(C)CC2)C=C1 LJIOTBMDLVHTBO-CUYJMHBOSA-N 0.000 description 3
- VUDZSIYXZUYWSC-DBRKOABJSA-N (4r)-1-[(2r,4r,5r)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-hydroxy-1,3-diazinan-2-one Chemical compound FC1(F)[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)N[C@H](O)CC1 VUDZSIYXZUYWSC-DBRKOABJSA-N 0.000 description 3
- IGVKWAAPMVVTFX-BUHFOSPRSA-N (e)-octadec-5-en-7,9-diynoic acid Chemical compound CCCCCCCCC#CC#C\C=C\CCCC(O)=O IGVKWAAPMVVTFX-BUHFOSPRSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 206010035664 Pneumonia Diseases 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 241000315672 SARS coronavirus Species 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000012267 brine Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 238000007865 diluting Methods 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000007850 fluorescent dye Substances 0.000 description 3
- 238000007710 freezing Methods 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- UPSFMJHZUCSEHU-JYGUBCOQSA-N n-[(2s,3r,4r,5s,6r)-2-[(2r,3s,4r,5r,6s)-5-acetamido-4-hydroxy-2-(hydroxymethyl)-6-(4-methyl-2-oxochromen-7-yl)oxyoxan-3-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide Chemical compound CC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](O)[C@@H](NC(C)=O)[C@H](OC=2C=C3OC(=O)C=C(C)C3=CC=2)O[C@@H]1CO UPSFMJHZUCSEHU-JYGUBCOQSA-N 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 235000005985 organic acids Nutrition 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 229940124531 pharmaceutical excipient Drugs 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- JQSHBVHOMNKWFT-DTORHVGOSA-N varenicline Chemical compound C12=CC3=NC=CN=C3C=C2[C@H]2C[C@@H]1CNC2 JQSHBVHOMNKWFT-DTORHVGOSA-N 0.000 description 3
- 101800000535 3C-like proteinase Proteins 0.000 description 2
- 101800002396 3C-like proteinase nsp5 Proteins 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 241000712891 Arenavirus Species 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000711404 Avian avulavirus 1 Species 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102400000888 Cholecystokinin-8 Human genes 0.000 description 2
- 101800005151 Cholecystokinin-8 Proteins 0.000 description 2
- 208000001528 Coronaviridae Infections Diseases 0.000 description 2
- 241000709687 Coxsackievirus Species 0.000 description 2
- 241000725619 Dengue virus Species 0.000 description 2
- 201000004315 EAST syndrome Diseases 0.000 description 2
- 241001115402 Ebolavirus Species 0.000 description 2
- 241001466953 Echovirus Species 0.000 description 2
- 241000991587 Enterovirus C Species 0.000 description 2
- 241000711950 Filoviridae Species 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 241000711549 Hepacivirus C Species 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 241000724675 Hepatitis E virus Species 0.000 description 2
- 241000709721 Hepatovirus A Species 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 241000711467 Human coronavirus 229E Species 0.000 description 2
- 241001428935 Human coronavirus OC43 Species 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 241000712431 Influenza A virus Species 0.000 description 2
- 241000713196 Influenza B virus Species 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241000710842 Japanese encephalitis virus Species 0.000 description 2
- 241000712079 Measles morbillivirus Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 241000711386 Mumps virus Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 241000713112 Orthobunyavirus Species 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 241000711798 Rabies lyssavirus Species 0.000 description 2
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 2
- 241000702670 Rotavirus Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 241000723873 Tobacco mosaic virus Species 0.000 description 2
- 241000711975 Vesicular stomatitis virus Species 0.000 description 2
- 241000710886 West Nile virus Species 0.000 description 2
- 241000710772 Yellow fever virus Species 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 230000002924 anti-infective effect Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 229940125808 covalent inhibitor Drugs 0.000 description 2
- 239000012954 diazonium Substances 0.000 description 2
- 150000001989 diazonium salts Chemical class 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000006196 drop Substances 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000012442 inert solvent Substances 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 2
- 239000012669 liquid formulation Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- REPVNSJSTLRQEQ-UHFFFAOYSA-N n,n-dimethylacetamide;n,n-dimethylformamide Chemical compound CN(C)C=O.CN(C)C(C)=O REPVNSJSTLRQEQ-UHFFFAOYSA-N 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000000816 peptidomimetic Substances 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 201000004193 respiratory failure Diseases 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- TYFQFVWCELRYAO-UHFFFAOYSA-N suberic acid Chemical compound OC(=O)CCCCCCC(O)=O TYFQFVWCELRYAO-UHFFFAOYSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 229940051021 yellow-fever virus Drugs 0.000 description 2
- FANCTJAFZSYTIS-IQUVVAJASA-N (1r,3s,5z)-5-[(2e)-2-[(1r,3as,7ar)-7a-methyl-1-[(2r)-4-(phenylsulfonimidoyl)butan-2-yl]-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol Chemical compound C([C@@H](C)[C@@H]1[C@]2(CCCC(/[C@@H]2CC1)=C\C=C\1C([C@@H](O)C[C@H](O)C/1)=C)C)CS(=N)(=O)C1=CC=CC=C1 FANCTJAFZSYTIS-IQUVVAJASA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- VIMMECPCYZXUCI-MIMFYIINSA-N (4s,6r)-6-[(1e)-4,4-bis(4-fluorophenyl)-3-(1-methyltetrazol-5-yl)buta-1,3-dienyl]-4-hydroxyoxan-2-one Chemical class CN1N=NN=C1C(\C=C\[C@@H]1OC(=O)C[C@@H](O)C1)=C(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 VIMMECPCYZXUCI-MIMFYIINSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical class NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 229940125673 3C-like protease inhibitor Drugs 0.000 description 1
- WCKQPPQRFNHPRJ-UHFFFAOYSA-N 4-[[4-(dimethylamino)phenyl]diazenyl]benzoic acid Chemical compound C1=CC(N(C)C)=CC=C1N=NC1=CC=C(C(O)=O)C=C1 WCKQPPQRFNHPRJ-UHFFFAOYSA-N 0.000 description 1
- MITGKKFYIJJQGL-UHFFFAOYSA-N 9-(4-chlorobenzoyl)-6-methylsulfonyl-2,3-dihydro-1H-carbazol-4-one Chemical compound ClC1=CC=C(C(=O)N2C3=CC=C(C=C3C=3C(CCCC2=3)=O)S(=O)(=O)C)C=C1 MITGKKFYIJJQGL-UHFFFAOYSA-N 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000034048 Asymptomatic disease Diseases 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 108090000552 Caspase-2 Proteins 0.000 description 1
- 102000004046 Caspase-2 Human genes 0.000 description 1
- 108090000712 Cathepsin B Proteins 0.000 description 1
- 102000004225 Cathepsin B Human genes 0.000 description 1
- 102000003908 Cathepsin D Human genes 0.000 description 1
- 108090000258 Cathepsin D Proteins 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- 102100031673 Corneodesmosin Human genes 0.000 description 1
- 101710139375 Corneodesmosin Proteins 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 244000309467 Human Coronavirus Species 0.000 description 1
- 241001109669 Human coronavirus HKU1 Species 0.000 description 1
- 241000482741 Human coronavirus NL63 Species 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 206010024971 Lower respiratory tract infections Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- HPKJGHVHQWJOOT-ZJOUEHCJSA-N N-[(2S)-3-cyclohexyl-1-oxo-1-({(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}amino)propan-2-yl]-1H-indole-2-carboxamide Chemical compound C1C(CCCC1)C[C@H](NC(=O)C=1NC2=CC=CC=C2C=1)C(=O)N[C@@H](C[C@H]1C(=O)NCC1)C=O HPKJGHVHQWJOOT-ZJOUEHCJSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical class O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 206010053159 Organ failure Diseases 0.000 description 1
- 208000019202 Orthocoronavirinae infectious disease Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 206010034972 Photosensitivity reaction Diseases 0.000 description 1
- 108010076039 Polyproteins Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 101710153041 Replicase polyprotein 1a Proteins 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 208000037847 SARS-CoV-2-infection Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 239000012505 Superdex™ Substances 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000000181 anti-adherent effect Effects 0.000 description 1
- 239000003911 antiadherent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000012084 conversion product Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000006240 deamidation Effects 0.000 description 1
- 238000007257 deesterification reaction Methods 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000012067 demethylated product Substances 0.000 description 1
- 230000017858 demethylation Effects 0.000 description 1
- 238000010520 demethylation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 230000023611 glucuronidation Effects 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- XMBWDFGMSWQBCA-YPZZEJLDSA-N iodane Chemical compound [125IH] XMBWDFGMSWQBCA-YPZZEJLDSA-N 0.000 description 1
- 229940044173 iodine-125 Drugs 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- INQOMBQAUSQDDS-BJUDXGSMSA-N iodomethane Chemical class I[11CH3] INQOMBQAUSQDDS-BJUDXGSMSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- YDCHPLOFQATIDS-UHFFFAOYSA-N methyl 2-bromoacetate Chemical compound COC(=O)CBr YDCHPLOFQATIDS-UHFFFAOYSA-N 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000007886 mutagenicity Effects 0.000 description 1
- 231100000299 mutagenicity Toxicity 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 208000007578 phototoxic dermatitis Diseases 0.000 description 1
- 231100000018 phototoxicity Toxicity 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 239000012744 reinforcing agent Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000002165 resonance energy transfer Methods 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 208000026425 severe pneumonia Diseases 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229910001495 sodium tetrafluoroborate Inorganic materials 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- ISIJQEHRDSCQIU-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[4.5]decane-7-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC11CNCC1 ISIJQEHRDSCQIU-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 230000017613 viral reproduction Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
- 206010048282 zoonosis Diseases 0.000 description 1
- 244000059546 zoonotic virus Species 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了具有通式I所示结构的三嗪类化合物或其药学上可接受的盐、异构体、代谢产物、前药、溶剂合物或水合物,药物组合物和用途。本发明克服了现有抗冠状病毒药物结构单一、非共价类高效小分子抑制剂缺乏等缺陷,本发明提供的三嗪类类化合物对3C样半胱氨酸蛋白酶具有很好的抑制活性,具有优良的药代动力学性质,且对感染性疾病有良好的治疗作用。
Description
技术领域
本发明属于创新药物化学领域,涉及一种三嗪类化合物、其制备方法、药物组合物及应用。
背景技术
冠状病毒(CoV)是一种包膜正链RNA致病病毒家族,可导致急性和慢性疾病,包括中枢神经系统疾病、普通感冒、下呼吸道感染和腹泻。HCoV-229E和HCoV-OC43是自1995年以来首次发现的人畜共患病毒株。2003年,严重急性呼吸综合征冠状病毒,现在命名为SARS-CoV-1,造成第一次全球人类冠状病毒大流行,导致8000多人进行性呼吸衰竭和916人死亡(病死率为10~15%)。在随后8年中,人们又发现了致命性明显降低的人畜共患病冠状病毒HCoV-NL64和HCoV-HKU1。2012年,类似SARs的中东呼吸综合征冠状病毒(MERS-CoV)被发现,该类病毒虽然具有较低的传播速率,但死亡率很高,自2012年出现至2021年2月2日,全球共有2567名确诊感染患者,死亡人数882人(死亡率34%)。2020年,由重症急性呼吸综合症冠状病毒-2(SARS-CoV-2)所引起的新型冠状病毒肺炎(COVID-19)目前正在全球蔓延,已经成为世界流行性疾病,给全球公共卫生防御和医疗系统带来严峻的挑战,给世界经济带来不确定因素。SARS-CoV-2是一种高致病性、大规模流行的人畜共患病毒,其与SARS-CoV-1和MERS-CoV同属于冠状病毒科。这三种病毒与其他几种冠状病毒HCoV-NL63、HCoV-229E、HCoV-OC43和HCoVHKU1不同,它们能够导致严重的呼吸道疾病。SARS-CoV-2感染的症状从无症状疾病到中度和重度肺炎,以及危及生命的并发症,包括低氧性呼吸衰竭、急性呼吸窘迫综合征、多系统器官衰竭,并最终出现死亡。更可怕的是,这种病毒不仅具有高度传染性,而且可以通过无症状感染者和那些处于症状期和症状前阶段的人进行传播。尽管目前全球已有多种不同的疫苗被批准上市或者获得紧急使用权,但是全球范围内有相当大的一部分群体由于自身的身体条件或者当地的医疗条件的限制而不能接种疫苗。另外,SARS-CoV-2病毒的S蛋白出现的疫苗逃逸突变对疫苗的有效性也提出了潜在的挑战,因而有效的抗新冠药物研发依然迫在眉睫。
冠状病毒进入宿主细胞后会被分解释放出核衣壳和病毒基因组。宿主细胞核糖体将病毒基因组的开放阅读框架(ORF)1a和ORF1b分别翻译成多聚蛋白pp1a和pp1b,用于编码16个非结构蛋白(nsps),而其余的ORF编码结构蛋白和附属蛋白。3C样半胱氨酸蛋白酶(3CLpro)和木瓜样半胱氨酸蛋白酶(PLpro)催化PP裂解生成nsp2-16,进而形成复制-转录复合体(RTC)。这些蛋白酶活性缺失会导致病毒生命周期停止。并且,3CLpro的结构和功能在冠状病毒中高度保守。因此,3CLpro成为开发抗广谱冠状病毒药物的潜在有效靶点。目前报道的3CLpro抑制剂包括共价拟肽类抑制剂和非共价小分子抑制剂。拟肽类共价抑制剂虽然对3CLpro具有显著的抑制活性,但是共价抑制剂靶点选择性较差,存在不可预测的毒副作用以及代谢稳定性差等问题。非共价小分子抑制剂是更好的选择,然而目前报道的非共价小分子抑制剂非常匮乏,存在结构单一、酶抑制活性较弱、成药性较差等问题。
日本盐野义制药公司报道的非共价Mpro小分子抑制剂S-217662目前处于临床2/3期,该公司目前已经报道了部分积极临床研究结果。该化合物能够显著抑制包括α、β、γ和Omicron等多种SARS-CoV-2变异株,表明其作为治疗新冠的治疗剂具有广泛的应用潜力。而且S-217622对一系列冠状病毒显示出广泛的抗病毒活性。S-217622对caspase-2、胰凝乳蛋白酶、组织蛋白酶B/D/G/L、凝血酶等宿主细胞蛋白酶在100μM范围内均无抑制活性,说明S-217622对冠状病毒蛋白酶具有很高的选择性。此外,S-217622的体外研究中没有发现hERG抑制、致突变性/致裂性和光毒性等安全性问题。
氘为氢在自然界中的一种稳定形态的非放射性同位素,无毒、无放射性,C-D键比C-H键更加稳定。将药物分子中的氢用氘取代后,可能封闭代谢位点、减少有毒代谢物的生成、延长药物在体内的半衰期,同时不影响药理活性。自2000年以来,氘代策略便被广泛应用于药物的研究中。氘代的S-217622相对于S-217622具有更优良的药代动力学性质,包括药物血药浓度提高、半衰期延长、降低了单次给药剂量。
发明内容
本发明要解决的技术问题是克服现有抗抗新冠药物严重匮乏、非共价类高效3CLpro小分子抑制剂缺乏,而提供了一种三嗪类化合物、其制备方法、药物组合物及应用。本发明的三嗪类化合物是一种活性显著的3CLpro非共价小分子抑制剂,且对冠状病毒感染性疾病具有较好的治疗作用。
本发明通过以下技术方案解决上述技术问题。
本发明提供了一种具有通式I所示结构的三嗪类化合物或其药学上可接受的盐、异构体、代谢产物、前药、溶剂合物或水合物,结构如下:
其中,R1、R2、R3、R4、R5、R6、R7或R8独立地选自氢或氘;
并且,R1、R2、R3、R4、R5、R6、R7或R8中至少有一个为氘。
在一些实施方案中,具有通式I所示结构的三嗪类化合物或其药学上可接受的盐、异构体、代谢产物、前药、溶剂合物或水合物,其特征在于,所述的R1、R2、R3、R4、R5或R6至少有一个为氘。
在一些实施方案中,具有通式I所示结构的三嗪类化合物或其药学上可接受的盐、异构体、代谢产物、前药、溶剂合物或水合物,其特征在于,所述的R1、R2或R3至少有一个为氘。
在一些实施方案中,具有通式I所示结构的三嗪类化合物或其药学上可接受的盐、异构体、代谢产物、前药、溶剂合物或水合物,其特征在于,所述的R4、R5或R6至少有一个为氘。
在一些实施方案中,具有通式I所示结构的三嗪类化合物或其药学上可接受的盐、异构体、代谢产物、前药、溶剂合物或水合物,其特征在于,所述的R7或R8至少有一个为氘。
在一些实施方案中,具有通式I所示结构的三嗪类化合物或其药学上可接受的盐、异构体、代谢产物、前药、溶剂合物或水合物,其特征在于,所述的R7和R8均为氘。
在一些实施方案中,具有通式I所示结构的化合物为以下任一化合物:
本发明提供一种具有通式I所示结构的三嗪类化合物、或其药学上可接受的盐、异构体或代谢产物制备方法,其包括以下步骤:在溶剂中,在碱的作用下,将如式II所示化合物与如式III所示化合物进行如下所示的反应,即可;
其中,R1、R2、R3、R4、R5、R6、R7和R8定义如权利要求1和2所述。
本发明还提供了一种具有通式I所示结构的三嗪类类化合物、或其药学上可接受的盐、异构体或代谢产物在制备3C样半胱氨酸蛋白酶抑制剂中的用途。
本发明还提供了一种具有通式I所示结构的三嗪类化合物、或其药学上可接受的盐、异构体或代谢产物在制备治疗和/或预防病毒感染性疾病药物中的用途。
进一步地,所述的病毒包括但不限于中东综合征相关冠状病毒(MERS-CoV)、严重急性呼吸综合征相关冠状病毒(SARS-CoV)、甲型流感病毒、乙型流感病毒、新型冠状病毒肺炎(COVID-19)、西班牙流感病毒、沙粒病毒、布尼亚病毒、狂犬病毒、禽流感病毒、骨髓灰质炎病毒、鼻病毒、腺病毒、埃博拉病毒、肠病毒、甲型肝炎病毒、丙型肝炎病毒、戊型肝炎病毒、肠病毒、HIV病毒、艾柯病毒、丝状病毒、麻疹病毒、黄热病病毒、日本脑炎病毒、西尼罗河病毒、新城病病毒、RS病毒、水泡性口炎病毒、流行性腮腺炎病毒、登革热病毒、柯萨奇病毒、轮状病毒或烟草花叶病毒。
本发明还提供了一种药物组合物,其含有具有通式I所示结构的三嗪类化合物、或其药学上可接受的盐、异构体或代谢产物,及药学上可接受的载体或辅料。
在所述的药物组合物中,所述的如通式I所示结构的三嗪类化合物、或其药学上可接受的盐、异构体或代谢产物用量为治疗有效量。
本发明还提供了上述药物组合物在制备3C样半胱氨酸蛋白酶抑制剂中的用途。
本发明还提供了上述药物组合物在制备治疗和/或预防病毒感染性疾病药物中的用途。
进一步地,所述的病毒包括但不限于中东综合征相关冠状病毒(MERS-CoV)、严重急性呼吸综合征相关冠状病毒(SARS-CoV)、甲型流感病毒、乙型流感病毒、新型冠状病毒肺炎(COVID-19)、西班牙流感病毒、沙粒病毒、布尼亚病毒、狂犬病毒、禽流感病毒、骨髓灰质炎病毒、鼻病毒、腺病毒、埃博拉病毒、肠病毒、甲型肝炎病毒、丙型肝炎病毒、戊型肝炎病毒、肠病毒、HIV病毒、艾柯病毒、丝状病毒、麻疹病毒、黄热病病毒、日本脑炎病毒、西尼罗河病毒、新城病病毒、RS病毒、水泡性口炎病毒、流行性腮腺炎病毒、登革热病毒、柯萨奇病毒、轮状病毒或烟草花叶病毒。
所述的药用辅料可为药物生产领域中广泛采用的那些辅料。辅料主要用于提供一个安全、稳定和功能性的药物组合物,还可以提供方法,使受试者接受给药后活性成分以所期望速率溶出,或促进受试者接受组合物给药后活性成分得到有效吸收。所述的药用辅料可以是惰性填充剂,或者提供某种功能,例如稳定该组合物的整体pH值或防止组合物活性成分的降解。所述的药用辅料可以包括下列辅料中的一种或多种:粘合剂、助悬剂、乳化剂、稀释剂、填充剂、成粒剂、胶粘剂、崩解剂、润滑剂、抗粘着剂、助流剂、润湿剂、胶凝剂、吸收延迟剂、溶解抑制剂、增强剂、吸附剂、缓冲剂、螯合剂、防腐剂、着色剂、矫味剂和甜味剂。
本发明的药物组合物可根据公开的内容使用本领域技术人员已知的任何方法来制备。例如,常规混合、溶解、造粒、乳化、磨细、包封、包埋或冻干工艺。
本发明所述的药物组合物可以任何形式给药,包括注射(静脉内)、粘膜、口服(固体和液体制剂)、吸入、眼部、直肠、局部或胃肠外(输注、注射、植入、皮下、静脉内、动脉内、肌内)给药。本发明的药物组合物还可以是控释或延迟释放剂型(例如脂质体或微球)。固体口服制剂的实例包括但不限于粉末、胶囊、囊片、软胶囊剂和片剂。口服或粘膜给药的液体制剂实例包括但不限于悬浮液、乳液、酏剂和溶液。局部用制剂的实例包括但不限于乳剂、凝胶剂、软膏剂、乳膏剂、贴剂、糊剂、泡沫剂、洗剂、滴剂或血清制剂。胃肠外给药的制剂实例包括但不限于注射用溶液、可以溶解或悬浮在药学上可接受载体中的干制剂、注射用悬浮液和注射用乳剂。所述的药物组合物的其它合适制剂的实例包括但不限于滴眼液和其他眼科制剂;气雾剂:如鼻腔喷雾剂或吸入剂;适于胃肠外给药的液体剂型;栓剂以及锭剂。
术语“药学上可接受的盐”是指本发明化合物的盐,由本发明发现的具有特定取代基的化合物与相对无毒的酸或碱制备。当本发明的化合物中含有相对酸性的功能团时,可以通过在纯的溶液或合适的惰性溶剂中用足够量的碱与这类化合物的游离体形式接触的方式获得碱加成盐。药学上可接受的碱加成盐包括钠、钾、钙、铵、有机氨或镁盐或类似的盐。当本发明的化合物中含有相对碱性的官能团时,可以通过在纯的溶液或合适的惰性溶剂中用足够量的酸与这类化合物的游离体形式接触的方式获得酸加成盐。药学上可接受的酸加成盐的实例包括无机酸盐,所述无机酸包括例如盐酸、氢溴酸、硝酸、碳酸(形成碳酸盐或碳酸氢盐)、磷酸(形成磷酸盐、磷酸一氢盐、磷酸二氢盐、硫酸(形成硫酸盐或硫酸氢盐)、氢碘酸、亚磷酸等;以及有机酸盐,所述有机酸包括如乙酸、丙酸、异丁酸、马来酸、丙二酸、苯甲酸、琥珀酸、辛二酸、反丁烯二酸、乳酸、扁桃酸、邻苯二甲酸、苯磺酸、对甲苯磺酸、柠檬酸、酒石酸和甲磺酸等类似的酸;有机酸盐还包括氨基酸(如精氨酸等)的盐,以及如葡糖醛酸等有机酸的盐。本发明的某些特定的化合物含有碱性和酸性的官能团,从而可以被转换成任一碱或酸加成盐。优选地,以常规方式使盐与碱或酸接触,再分离母体化合物,由此再生化合物的游离体形式。化合物的游离体形式与其各种盐的形式的不同之处在于某些物理性质,例如在极性溶剂中的溶解度不同。
本发明的“药学上可接受的盐”可由含有酸根或碱基的母体化合物通过常规化学方法合成。一般情况下,这样的盐的制备方法是:在水或有机溶剂或两者的混合物中,经由游离酸或碱形式的这些化合物与化学计量的适当的碱或酸反应来制备。一般地,优选醚、乙酸乙酯、乙醇、异丙醇或乙腈等非水介质。
术语“异构体”是指具有相同化学式而有不同的原子排列的化合物。
术语“代谢产物”是指式I所示化合物或其盐通过体内代谢产生的药学活性产物。这种产物可以从例如所给药的化合物的氧化、还原、水解、酰胺化、脱酰胺、酯化、脱酯、葡糖醛酸化、酶促裂解等产生。因此,本发明包括本发明的化合物的代谢产物,包括使本发明的化合物与哺乳动物接触足够得到其代谢产物的一段时间的方法而产生的化合物。
代谢产物的鉴定典型地通过制备本发明化合物的放射性标记的同位素、将其以可检测的剂量(例如,大于约0.5mg/kg)非肠道给予动物,例如大鼠、小鼠、豚鼠、猴、或人,允许充分的时间以发生代谢(典型地约30秒到30小时)和从尿、血液或其它生物样本分离其转化产物。这些产物容易分离,因为它们是被标记的(其它通过利用能够结合存在于代谢物中的抗原表位的抗体分离)。以常规的方式确定代谢物结构,例如,通过MS,LC/MS或NMR分析。通常,代谢物的分析是以与本领域技术人员公知的常规药物代谢研究相同的方法进行的。只要代谢物产物不是以其它方式在体内不能被发现,否则它们可用于本发明化合物的治疗剂量给药的检定测定法。本发明的化合物可以在一个或多个构成该化合物的原子上包含非天然比例的原子同位素。例如,可用放射性同位素标记化合物,比如氚(3H),碘-125(125I)或C-14(14C)。本发明的化合物的所有同位素组成的变换,无论放射性与否,都包括在本发明的范围之内。
在不违背本领域常识的基础上,上述各优选条件,可任意组合,即得本发明各较佳实例。
本发明所用试剂和原料均市售可得。
本发明的积极进步效果在于:
(1)本发明的氘代三嗪类化合物对3C样半胱氨酸蛋白酶具有很好的抑制活性。
(2)本发明化合物能够有效提高血药浓度、延长半衰期,并且显著降低了单次给药剂量。
(3)本发明化合物对冠状病毒感染具有较好的治疗作用。
附图说明
图1为实施例14种阳性对照组和化合物S11在小鼠感染模型中的抗感染活性。
具体实施方式
下面通过实施例的方式进一步说明本发明,但并不因此将本发明限制在所述的实施例范围之中。下列实施例中未注明具体条件的实验方法,按照常规方法和条件,或按照商品说明书选择。
实施例1:化合物S1的合成
步骤一:氘代化合物4a的合成
(1)化合物1(37.2g,0.2mol)混悬于水(190ml)和浓盐酸(50ml,0.6mol)中,0℃下,将NaNO2水溶液(13.80g,0.2mol,32.20mL)滴加至上述溶液中,然后搅拌30min,过滤,预冷的NaBF4(24.20g,0.22mol)的水溶液(90ml)加入到上述滤液中,0℃下搅拌40min。停止搅拌,过滤,冷乙醇和乙醚洗涤滤饼,收集滤饼、干燥制得重氮盐(22.5g,0.097mol)。将重氮盐溶于CHCl3(231mL),将KOAc(15.15g,0.155mol)加入到上述溶液中,室温下搅拌,TLC监测,反应完全,停止搅拌。加水(200ml)淬灭反应,DCM萃取(100mL ×3),合并有机相,饱和食盐水洗涤,无水Na2SO4干燥,过滤,浓缩,重结晶制得化合物2(25.49g,65%)。1H NMR(300MHz,Chloroform-d)δ9.11(s,1H),8.73(d,J=1.4Hz,1H),8.34(d,J=1.4Hz,1H),7.77(s,1H)。
(2)将化合物2(19.6g,0.1mol)溶于无水DMF(300ml)中,0℃下,分批加入NaH(4.8g,0.12mol),维持0℃搅拌30min,然后向上述混悬液中加入氘代碘甲烷(15.9g,0.11mol),转移至室温,继续搅拌反应,TLC监测,直至原料反应完全。停止反应,将反应液置于0℃下,饱和氯化铵溶液(200ml)淬灭反应,DCM萃取(100ml×3),合并有机相,饱和食盐水洗涤,无水Na2SO4干燥,过滤,浓缩,柱层析纯化,制得化合物3(14.98g,70%)。1H NMR(300MHz,Chloroform-d)δ8.75(d,J=1.5Hz,1H),8.03(d,J=1.5Hz,1H),7.80(s,1H)。
(3)将化合物3a(10g,0.047mol)溶于甲醇/四氢呋喃(100ml)中,加入甲酸铵(0.187mol,11.8g)和Pd/C(1g),加热回流,TLC监测,直至原料反应完全。停止反应,硅藻土抽滤,滤液浓缩,加入DCM溶解(300ml),水洗,饱和食盐水洗涤,无水Na2SO4干燥,过滤,浓缩,柱层析分离纯化,制得化合物4(7.8g,90%)。1H NMR(300MHz,Chloroform-d)δ7.93–7.85(m,2H),7.34(d,J=1.5Hz,1H),5.75(s,2H).
步骤二:化合物S1的合成
(1)化合物6a的合成
将化合物5(100mg,0.436mmol)溶于乙腈(2ml)中,向上述溶液中加入碳酸钾(78.0mg,0.567mmol)和化合物12a(0.063mL,0.480mmol),加热回流反应2h。冷却至室温,乙酸乙酯稀释反应液,抽滤,滤液浓缩,柱层析分离纯化制得化合物6a(151mg,93%)。1H NMR(300MHz,Chloroform-d)δ1.33(3H,t,J=7.4Hz),1.65(9H,s),3.15(2H,q,J=7.4Hz),5.03(2H,s),6.91-7.01(2H,m).
(2)化合物7a的合成
向化合物6a(4.88g,13.08mmol)中加入TFA(9.8mL),室温下搅拌反应过夜,浓缩,异丙醚打浆,抽滤,收集滤饼,干燥,制得化合物7a(4.01g,97%)。1H NMR(400MHz,Chloroform-d)δ1.36(3H,t,J=7.4Hz),3.20(2H,q,J=7.4Hz),5.16(2H,s),6.97-7.08(2H,m),8.25(1H,br s)。
(3)化合物8a的合成
将化合物7a(2.50g,7.88mmol)溶于DMF(15ml)中,向上述溶液中加入溴乙酸甲酯(1.2ml,11.8mmol),碳酸钾(3.27g,23.6mmol)和碘化钾(130mg,0.788mol),加热至60℃,反应4h。冷却至室温,加入DCM稀释反应液,水洗,饱和食盐水洗涤,无水Na2SO4干燥,过滤,浓缩,柱层析分离纯化,制得化合物8a(2.51g,85%)。1H NMR(300MHz,Chloroform-d)δ7.08(dtt,J=7.9,5.0,1.0Hz,1H),6.94(td,J=8.0,4.9Hz,1H),5.05(d,J=0.9Hz,2H),4.55(s,2H),3.75(s,3H),2.53(s,3H).
(4)化合物9a的合成
将化合物8a(3.75g,10mmol)溶于甲醇(30ml)中,加入NaOH水溶液(2M,20mol,10ml),室温下搅拌2h。将反应液转移至0℃下,稀盐酸调节pH至2~3,抽滤,收集滤饼,烘干,得到8a脱甲酯的产物。将8a脱甲酯产物溶于无水THF(20ml)中,-5℃下,向上述溶液中滴加氯甲酸异丁酯(1.6ml,12mmol)和三乙胺(2ml,15mmol),搅拌30min。抽滤,滤液浓缩,加入无水THF(20ml)溶解,0℃下,加入氨/甲醇(7M,50mmol,7ml),转移至室温搅拌1h。抽滤,滤液加入DCM稀释,水洗,饱和食盐水洗涤,无水硫酸钠干燥,过滤,浓缩,柱层析分离纯化,制得化合物9a(3.24g,90%)。1H NMR(300MHz,Chloroform-d)δ7.16-7.22(m,1H),7.08(s,2H),6.94(td,J=8.0,5.0Hz,1H),5.06(d,J=1.1Hz,2H),4.56(s,2H),2.59(s,3H).
(5)化合物10a的合成
将化合物9a(3.6g,10mmol)混悬于DMF-DMA(1.5ml,11mmol)中,加热至95℃,加热30min后,冷却至室温,减压蒸掉DMF-DMA,加入1,2-二氯乙烷形成共沸物,以保证DMF-DMA除干净。然后将上述油状物溶于乙醇(7ml)中,无需纯化直接投入后面的反应。乙醇(30ml)和醋酸(7ml)的混合液在冰浴条件下冷却,向上述溶液中滴加水合肼(4ml,11mol),滴加完毕后,将前面得到的中间体的乙醇溶液缓慢滴加至上述反应液中,滴加完成后,转移至室温,搅拌反应,TLC监测,直至原料反应完全,停止反应,减压蒸掉乙醇,加水稀释,过滤,水洗涤滤饼,收集滤饼,干燥,制得化合物10a(1.92g,50%)。1H NMR(300MHz,Chloroform-d)δ9.11(s,1H),8.60(d,J=4.6Hz,1H),7.12(dtt,J=8.0,5.0,1.0Hz,1H),6.97(td,J=8.1,5.0Hz,1H),5.06(d,J=1.1Hz,2H),4.29(s,2H),2.53(s,3H).
(6)化合物11a的合成
将化合物10a(3.84g,10mmol)溶于DMF(20ml)中,加入碳酸钾(3.45g,25mmol),碘甲烷(7.5ml,12mmol),升温至80℃,反应5h。冷却至室温,抽滤,DCM稀释反应液,水洗,饱和食盐水洗涤,无水硫酸钠干燥,过滤,浓缩,柱层析分离纯化,制得化合物11a。1H NMR(300MHz,Chloroform-d)δ8.24(s,1H),7.12(dtt,J=8.0,4.9,1.0Hz,1H),6.97(td,J=8.1,5.0Hz,1H),5.06(d,J=1.1Hz,2H),4.68(d,J=12.4Hz,1H),4.29(d,J=12.5Hz,1H),4.09(s,3H),2.57(s,3H).
(4)化合物S1的合成
0℃下,向化合物10a(300mg,0.727mmol)和4(172mg,0.946mmol)的四氢呋喃溶液中滴加LHMDS(1M,1.46mL,1.46mmol),维持0℃搅拌3h,然后转移至室温搅拌40min。反应完成后,加入饱和氯化铵溶液(2ml)淬灭反应,乙酸乙酯萃取(2ml×3),合并有机相,饱和食盐水洗涤,无水Na2SO4干燥,过滤,浓缩,柱层析纯化,制得化合物S1。1H NMR(300MHz,DMSO-d6,DCl in D2O)δ3.94(3H,s),5.08(2H,s),5.36(2H,s),7.46(1H,m),7.48-7.62(2H,m),7.77(1H,s),8.42(1H,s),9.32(1H,s).MS(ESI,m/z):535(M++1).
实施例2:化合物S2的合成
合成方法如实施例1,只需更换相应的原料即可。1H NMR(300MHz,DMSO-d6,DCl inD2O)δ9.32(1H,s),8.42(1H,s),7.77(1H,s),7.46(1H,m),5.36(2H,s),5.08(2H,s),4.18(3H,s),3.94(1H,s).MS(ESI,m/z):534(M++1).
实施例3:化合物S3的合成
合成方法如实施例1,只需更换相应的原料即可。1H NMR(300MHz,DMSO-d6,DCl inD2O)δ9.32(1H,s),8.42(1H,s),7.77(1H,s),7.46(1H,m),5.36(2H,s),5.08(2H,s),4.18(3H,s),3.94(2H,s).MS(ESI,m/z):533(M++1).
实施例4:化合物S4的合成
合成方法如实施例1,只需更换相应的原料即可。1H NMR(300MHz,DMSO-d6,DCl inD2O)δ9.32(1H,s),8.42(1H,s),7.77(1H,s),7.46(1H,m),5.36(2H,s),5.08(2H,s),3.94(3H,s).MS(ESI,m/z):535(M++1).
实施例5:化合物S5的合成
合成方法如实施例1,只需更换相应的原料即可。1H NMR(300MHz,DMSO-d6,DCl inD2O)δ9.32(1H,s),8.42(1H,s),7.77(1H,s),7.46(1H,m),5.36(2H,s),5.08(2H,s),4.18(s,1H),3.94(3H,s).MS(ESI,m/z):534(M++1).
实施例6:化合物S6的合成
合成方法如实施例1,只需更换相应的原料即可。1H NMR(300MHz,DMSO-d6,DCl inD2O)δ9.32(1H,s),8.42(1H,s),7.77(1H,s),7.46(1H,m),5.36(2H,s),5.08(2H,s),4.18(s,2H),3.94(3H,s).MS(ESI,m/z):533(M++1).
实施例7:化合物S7的合成
合成方法如实施例1,只需更换相应的原料即可。1H NMR(300MHz,DMSO-d6,DCl inD2O)δ9.32(1H,s),8.42(1H,s),7.77(1H,s),7.46(1H,m),5.36(2H,s),5.08(2H,s),.MS(ESI,m/z):538(M++1).
实施例8:化合物S8的合成
合成方法如实施例1,只需更换相应的原料即可。1H NMR(300MHz,DMSO-d6,DCl inD2O)δ9.32(1H,s),8.42(1H,s),7.77(1H,s),7.46(1H,m),5.08(2H,s),4.18(3H,s).MS(ESI,m/z):537(M++1).
实施例9:化合物S9的合成
合成方法如实施例1,只需更换相应的原料即可。1H NMR(300MHz,DMSO-d6,DCl inD2O)δ9.32(1H,s),8.42(1H,s),7.77(1H,s),7.46(1H,m),5.08(2H,s),3.94(2H,s).MS(ESI,m/z):537(M++1).
实施例10:化合物S10的合成
合成方法如实施例1,只需更换相应的原料即可。1H NMR(300MHz,DMSO-d6,DCl inD2O)δ9.32(1H,s),8.42(1H,s),7.77(1H,s),7.46(1H,m),5.08(2H,s),4.18(s,3H),3.94(3H,s).MS(ESI,m/z):534(M++1).
实施例11:化合物S11的合成
合成方法如实施例1,只需更换相应的原料即可。1H NMR(300MHz,DMSO-d6,DCl inD2O)δ9.32(1H,s),8.42(1H,s),7.77(1H,s),7.46(1H,m),5.08(2H,s).MS(ESI,m/z):540(M++1).
实施例12:SARS-CoV-2病毒3C样半胱氨酸蛋白酶(3CLpro)酶抑制活性测试实验
1.3CLpro蛋白表达与纯化
将全长3CLpro蛋白的基因序列构建在表达载体pET28a(+)载体中并转入大肠杆菌BL21(DE3)感受态细胞,在终浓度0.5mM IPTG,25℃条件下诱导12小时后用Ni-NTA柱纯化。纯化得到的蛋白经SDS检测,纯度大于90%的部分用于进一步用GE蛋白质层析纯化系统AKTA Pure的Superdex 200 10/300GL纯化,得到纯度大于95%的蛋白,使用Nano Drop测定蛋白浓度,分装并液氮速冻后放入-80℃保存。
2.SARS-CoV-2 3CLpro酶活筛选体系的建立与抑制剂抑制率及药物IC50的计算
通过荧光共振能量转移(FRET)技术测定SARS-CoV-2 3CLpro活性及化合物对SARS-CoV-2 3CLpro的抑制活性。测定试验中使用带有SARS-CoV-2 3CLpro切割位点(箭头所示)的荧光底物(Dabcyl-KTSAVLQ↓SGFRKM-E(Edans)-NH2)和Tris-HCl缓冲液(20mMTris-HCl,150mM NaCl,10mM EDTA,pH 7.5)。化合物由100%DMSO溶解。10μl化合物与40μlSARS-CoV-2 3CLpro(终浓度0.5μM,Tris-HCl缓冲液稀释)在25℃孵育10min,通过添加50μl荧光底物(终浓度20μM)引发反应。使用放射共振能量转移荧光分光光度计在340nm激发波长和490nm吸收波长下检测由于3CLpro催化的底物裂解而产生的Dabcyl荧光信号。SARS-CoV-2 3CLpro动力学常数(Vmax和Km)是通过将数据拟合到Michaelis Menten方程中得出的,V=Vmax×[S]/(Km+[S])。然后根据公式kcat=Vmax/[E],计算kcat。使用Tris-HCl缓冲液将化合物按倍数稀释法进行梯度稀释,并使用上述相同终浓度的SARS-CoV-2 3CLpro和荧光底物体系进行测定。分别在存在和不存在目标化合物的情况下,确定3CLpro催化多肽底物水解的内在(V0i)和表观(Vappi,Kappi)催化参数的值。目标化合物与Mpro结合的表观抑制常数(Kappi)由Vappi对固定底物浓度([S])下抑制剂浓度([I])的依赖性根据方程Vappi=Vapp×[I]/(Kappi+[I])得出。目标化合物与3CLpro结合的内在抑制常数(Ki)的值根据方程Kappi=Ki×(1+[S]/Km)计算得出。化合物的抑制曲线由GraphPad Prism 8.0软件绘制并计算IC50值。其结果如下表1所示,实施例化合物对SARS-CoV-2病毒3CLpro具有较好的抑制活性,活性优于阳性药S-217622。
表1 SARS-CoV-2病毒3CLpro酶抑制活性
化合物编号 | IC<sub>50</sub>(μM) | 化合物编号 | IC<sub>50</sub>(μM) |
S1 | 0.018 | S7 | 0.012 |
S2 | 0.018 | S8 | 0.015 |
S3 | 0.015 | S9 | 0.0145 |
S4 | 0.018 | S10 | 0.020 |
S5 | 0.017 | S11 | 0.010 |
S6 | 0.016 | S-217622 | 0.025 |
实施例13:细胞毒性以及抗SARS-CoV-2病毒感染药效测试实验
Vero E6细胞毒性测试:采用CCK8法检测待测化合物对哺乳动物Vero E6细胞中的细胞毒性。Vero E6细胞加入到96孔板中,培养过夜。然后,细胞与不同浓度的待测化合物共孵育48h。除掉孔板中的培养基,换成新鲜无血清的培养基,加入10%CCK8试剂,再在37℃孵育1h,随后采用酶标仪检测450nm处吸光度值。
筛选无细胞毒性或细胞毒性较小的化合物进行抗病毒感染的测试,具体操作包括以下步骤:①接种细胞:取处于对数生长期的Vero-E6细胞,吸出培养液,用胰酶消化细胞,细胞计数为:1×106个/ml;取上述细胞4ml,加入培养基6ml,制备得到细胞密度为4×105个/ml的细胞悬液,接种到96孔板中,每孔100μl,每孔细胞4×104个。②药物预处理细胞:将细胞培养基更换为含有2%FBS的DMEM培养基,加入相应浓度的药物和DMSO,每孔100μl,之后置于37℃培养箱,预处理1h。③病毒感染:取病毒0.3ml,加入45ml培养基,混匀,将病毒稀释至100TCID50/0.05ml;弃去细胞板中的药物培养基垂直悬滴病毒稀释液至96孔板内,加样体积50μl/孔,同时加入相应的药物培养基(含有相应浓度的药物),加样体积50μl/孔,混匀;④孵育:将加好样的细胞培养板在震荡器上混匀,置于37℃培养箱,孵育1h。孵育结束后,吸去接种有细胞的病毒-血清混合液,加入相应浓度的药物和对照组DMSO,加样体积100μl/孔(100TCID50/孔),置于37℃CO2培养箱中培养48h;⑤收集上清液体检测病毒RNA,用4%的多聚甲醛固定染色进行免疫荧光染色分析。
具体实验结果如表2所示,实施例化合物细胞毒性较小,对SARS-CoV-2病毒感染具有较好的抑制活性,且具有较好的选择指数。
表2待测化合物的细胞毒性和抗SARS-CoV-2病毒感染活性
实施例14:化合物S11体内抗感染活性测试
雌性BALB/c小鼠,首先通过腹腔注射氯胺酮/甲苯噻嗪(50mg/kg/5mg/kg)使其麻醉,然后将SARS-CoV-2γ株(1×104TCID50/只)通过鼻内接种构建感染模型,阴性对照组小鼠滴入相同体积的生理盐水。造模成功后,分为空白对照组、S-217622阳性对照组和给药组,每组6只。将化合物S-217622和S11分别混悬于0.5%甲基纤维素,造模成功后立即口服给药一次,12h后给药一次。S11的给药剂量为2mg/kg,8mg/kg,16mg/kg和32mg/kg,S-217622给药剂量为32mg/kg。病毒感染24h后,处死小鼠,观察小鼠肺部病毒滴度。
如图1所示,化合物S11给药两次后,相对于空白对照组,显著降低感染小鼠的肺匀浆中的病毒低毒,且呈剂量依赖性。阳性对照S-217622和化合物S11在16mg/kg和32mg/kg给药剂量下病毒滴度达到最低检出限。
实施例14:化合物S11的药代动力学性质测试
大鼠模型药代动力学性质测试:口服给药:将化合物用DMSO/0.5%甲基纤维素(400cP)(1:4)体系溶解,给药剂量2μM/5ml/kg。静脉给药:将化合物用DMSO/丙二醇(v/v=1:1),给药剂量(1.0μmol/mL/kg)。于给药后5min,15min,30min,1h,2h,4h,8h,10h,24h,从眼底静脉丛连续取血置于分布由肝素的EP管中,8000rpm/min离心5min后取上层血浆,-20℃冻存静脉注射给药,待LC-MS/MS分析,根据测试所得的血药浓度-时间数据,采用WinNonlin软件求算药代动力学参数。
比格犬药代动力学性质测试:口服给药:溶媒为0.5%甲基纤维素(400cP),给药剂量3mg/2mL/kg。静脉给药:溶媒为二甲基乙酰胺/乙醇/20%HP-β-CD(v:v:v=2:3:5)的碳酸盐缓冲液(pH 9.0)。于给药后5min,15min,30min,1h,2h,4h,8h,10h,24h,从眼底静脉丛连续取血置于分布由肝素的EP管中,8000rpm/min离心5min后取上层血浆,-20℃冻存静脉注射给药,待LC-MS/MS分析,根据测试所得的血药浓度-时间数据,采用WinNonlin软件求算药代动力学参数。
实验结果表明,化合物S11在大鼠中的口服生物利用度为97%,半衰期为5h;化合物S-217622在大鼠中的口服生物利用度为93%,半衰期为2.9h。化合物S11在比格犬中的口服生物利用度为77%,半衰期为30h;S-217622在比格犬中的口服生物利用度为69%,半衰期为28h。
Claims (10)
2.根据权利要求1所述的具有通式I所示结构的三嗪类化合物或其药学上可接受的盐、异构体、代谢产物、前药、溶剂合物或水合物,其特征在于,所述的R1、R2、R3、R4、R5或R6至少有一个为氘。
3.根据权利要求1和2所述的具有通式I所示结构的三嗪类化合物或其药学上可接受的盐、异构体、代谢产物、前药、溶剂合物或水合物,其特征在于,所述的R1、R2或R3至少有一个为氘。
4.根据权利要求1和2所述的具有通式I所示结构的三嗪类化合物或其药学上可接受的盐、异构体、代谢产物、前药、溶剂合物或水合物,其特征在于,所述的R4、R5或R6至少有一个为氘。
5.根据权利要求1所述的具有通式I所示结构的三嗪类化合物或其药学上可接受的盐、异构体、代谢产物、前药、溶剂合物或水合物,其特征在于,所述的R7或R8至少有一个为氘。
6.根据权利要求1和5所述的具有通式I所示结构的三嗪类化合物或其药学上可接受的盐、异构体、代谢产物、前药、溶剂合物或水合物,其特征在于,所述的R7和R8均为氘。
9.一种药物组合物,其特征在于,所述药物组合物含有治疗有效量的一种或多种权利要求1-7中任一所述的具有通式I所示结构的三嗪类化合物、或其药学上可接受的盐、异构体或代谢产物,及药学上可接受的载体或辅料。
10.一种如权利要求1-7中任一所述的具有通式I所示结构的三嗪类化合物、或其药学上可接受的盐、异构体或代谢产物的用途,其特征在于,用于制备3C样半胱氨酸蛋白酶抑制剂或用于制备治疗和/或预防病毒感染性疾病的药物,优选用于制备3C样半胱氨酸蛋白酶抑制剂或用于制备治疗和/或预防病毒感染性疾病的药物。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210247036.4A CN114539228A (zh) | 2022-03-14 | 2022-03-14 | 三嗪类化合物或其可药用盐、异构体、药物组合物和用途 |
PCT/CN2022/118629 WO2023173708A1 (zh) | 2022-03-14 | 2022-09-14 | 三嗪类化合物或其可药用盐、异构体、药物组合物和用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210247036.4A CN114539228A (zh) | 2022-03-14 | 2022-03-14 | 三嗪类化合物或其可药用盐、异构体、药物组合物和用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114539228A true CN114539228A (zh) | 2022-05-27 |
Family
ID=81663727
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210247036.4A Pending CN114539228A (zh) | 2022-03-14 | 2022-03-14 | 三嗪类化合物或其可药用盐、异构体、药物组合物和用途 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN114539228A (zh) |
WO (1) | WO2023173708A1 (zh) |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114790198A (zh) * | 2022-06-24 | 2022-07-26 | 北京科翔中升医药科技有限公司 | 一种三嗪类化合物及其制备方法和应用 |
CN114805316A (zh) * | 2022-05-31 | 2022-07-29 | 中国药科大学 | 二酮氮杂环化合物或其可药用的盐、互变异构体及其制备方法、药物组合物及应用 |
CN114933594A (zh) * | 2022-07-20 | 2022-08-23 | 北京科翔中升医药科技有限公司 | 一种氟代三嗪类化合物、药物组合物及用途 |
CN115109042A (zh) * | 2022-08-30 | 2022-09-27 | 北京科翔中升医药科技有限公司 | 三嗪类化合物或其可药用的盐、药物组合物和用途 |
CN115260166A (zh) * | 2022-07-13 | 2022-11-01 | 山东轩硕医药科技有限公司 | 一种高效合成s-217622的化学新方法 |
CN115260167A (zh) * | 2022-08-01 | 2022-11-01 | 陕西盘龙药业集团股份有限公司 | 一种3-四唑基甲基-1,3,5-三嗪-2,4-二酮类化合物及其制备方法和应用 |
CN115490681A (zh) * | 2022-07-08 | 2022-12-20 | 歌礼生物科技(杭州)有限公司 | 三嗪衍生物 |
CN115504968A (zh) * | 2022-11-21 | 2022-12-23 | 歌礼生物科技(杭州)有限公司 | 三嗪衍生物 |
CN115819407A (zh) * | 2022-12-13 | 2023-03-21 | 浙江乐普药业股份有限公司 | 一种Ensitrelvir类似物及其制备方法和抗新冠用途 |
WO2023155337A1 (zh) * | 2022-02-18 | 2023-08-24 | 广州谷森制药有限公司 | 新型氘代三嗪类化合物、其制备方法、组合物及应用 |
WO2023165459A1 (en) * | 2022-03-01 | 2023-09-07 | Fochon Biosciences , Ltd. | Compounds as sars-cov-2 inhibitors |
WO2023169572A1 (zh) * | 2022-03-10 | 2023-09-14 | 湖北九康通生物医药有限公司 | 一种三嗪类化合物、其中间体、其制备方法及其用途 |
WO2023173708A1 (zh) * | 2022-03-14 | 2023-09-21 | 药康众拓(江苏)医药科技有限公司 | 三嗪类化合物或其可药用盐、异构体、药物组合物和用途 |
WO2023227118A1 (zh) * | 2022-05-27 | 2023-11-30 | 广州国家实验室 | 3c样蛋白酶抑制剂 |
WO2024009120A1 (en) * | 2022-07-08 | 2024-01-11 | Ascletis Bioscience Co., Ltd. | Triazine derivatives and methods of use thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114507221A (zh) * | 2022-04-21 | 2022-05-17 | 北京科翔中升医药科技有限公司 | 一种三嗪类化合物及其在制备抗病毒药物上的用途 |
CN114790198A (zh) * | 2022-06-24 | 2022-07-26 | 北京科翔中升医药科技有限公司 | 一种三嗪类化合物及其制备方法和应用 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3188794A1 (en) * | 2020-08-11 | 2022-02-17 | William FITZSIMMONS | Methods of treating coronavirus infections by co-administering an fkbp ligand and an antiviral agent |
CN114539228A (zh) * | 2022-03-14 | 2022-05-27 | 药康众拓(江苏)医药科技有限公司 | 三嗪类化合物或其可药用盐、异构体、药物组合物和用途 |
-
2022
- 2022-03-14 CN CN202210247036.4A patent/CN114539228A/zh active Pending
- 2022-09-14 WO PCT/CN2022/118629 patent/WO2023173708A1/zh unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114507221A (zh) * | 2022-04-21 | 2022-05-17 | 北京科翔中升医药科技有限公司 | 一种三嗪类化合物及其在制备抗病毒药物上的用途 |
CN114790198A (zh) * | 2022-06-24 | 2022-07-26 | 北京科翔中升医药科技有限公司 | 一种三嗪类化合物及其制备方法和应用 |
Non-Patent Citations (5)
Title |
---|
JENNIFER L. MCKIMM-BRESCHKIN等: "COVID-19, Influenza and RSV: Surveillance-informed prevention and treatment – Meeting report from an isirv-WHO virtual conference treatment – Meeting report from an isirv-WHO virtual conference", 《ANTIVIRAL RESEARCH》 * |
MICHIHITO SASAKI等: "Oral administration of S-217622, a SARS-CoV-2 main protease 1 inhibitor, decreases viral load and accelerates recovery from clinical aspects of COVID-19", 《BIORXIV》 * |
YUTO UNOH等: "Discovery of S-217622, a Non-Covalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19", 《BIORXIV》 * |
李雪莹等: "氘代药物的专利技术进展", 《药学进展》 * |
王曦等: "氘代药物的研究进展", 《天津药学》 * |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023155337A1 (zh) * | 2022-02-18 | 2023-08-24 | 广州谷森制药有限公司 | 新型氘代三嗪类化合物、其制备方法、组合物及应用 |
WO2023165459A1 (en) * | 2022-03-01 | 2023-09-07 | Fochon Biosciences , Ltd. | Compounds as sars-cov-2 inhibitors |
WO2023169572A1 (zh) * | 2022-03-10 | 2023-09-14 | 湖北九康通生物医药有限公司 | 一种三嗪类化合物、其中间体、其制备方法及其用途 |
WO2023173708A1 (zh) * | 2022-03-14 | 2023-09-21 | 药康众拓(江苏)医药科技有限公司 | 三嗪类化合物或其可药用盐、异构体、药物组合物和用途 |
WO2023227118A1 (zh) * | 2022-05-27 | 2023-11-30 | 广州国家实验室 | 3c样蛋白酶抑制剂 |
CN114805316A (zh) * | 2022-05-31 | 2022-07-29 | 中国药科大学 | 二酮氮杂环化合物或其可药用的盐、互变异构体及其制备方法、药物组合物及应用 |
CN114805316B (zh) * | 2022-05-31 | 2024-04-26 | 中国药科大学 | 二酮氮杂环化合物或其可药用的盐、互变异构体及其制备方法、药物组合物及应用 |
CN114790198A (zh) * | 2022-06-24 | 2022-07-26 | 北京科翔中升医药科技有限公司 | 一种三嗪类化合物及其制备方法和应用 |
WO2024009120A1 (en) * | 2022-07-08 | 2024-01-11 | Ascletis Bioscience Co., Ltd. | Triazine derivatives and methods of use thereof |
CN115490681A (zh) * | 2022-07-08 | 2022-12-20 | 歌礼生物科技(杭州)有限公司 | 三嗪衍生物 |
CN115490681B (zh) * | 2022-07-08 | 2023-04-18 | 歌礼生物科技(杭州)有限公司 | 三嗪衍生物 |
CN115260166A (zh) * | 2022-07-13 | 2022-11-01 | 山东轩硕医药科技有限公司 | 一种高效合成s-217622的化学新方法 |
CN115260166B (zh) * | 2022-07-13 | 2023-12-19 | 山东轩硕医药科技有限公司 | 一种高效合成s-217622的化学方法 |
CN114933594A (zh) * | 2022-07-20 | 2022-08-23 | 北京科翔中升医药科技有限公司 | 一种氟代三嗪类化合物、药物组合物及用途 |
CN115260167A (zh) * | 2022-08-01 | 2022-11-01 | 陕西盘龙药业集团股份有限公司 | 一种3-四唑基甲基-1,3,5-三嗪-2,4-二酮类化合物及其制备方法和应用 |
CN115109042A (zh) * | 2022-08-30 | 2022-09-27 | 北京科翔中升医药科技有限公司 | 三嗪类化合物或其可药用的盐、药物组合物和用途 |
CN115504968A (zh) * | 2022-11-21 | 2022-12-23 | 歌礼生物科技(杭州)有限公司 | 三嗪衍生物 |
CN115819407A (zh) * | 2022-12-13 | 2023-03-21 | 浙江乐普药业股份有限公司 | 一种Ensitrelvir类似物及其制备方法和抗新冠用途 |
Also Published As
Publication number | Publication date |
---|---|
WO2023173708A1 (zh) | 2023-09-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN114539228A (zh) | 三嗪类化合物或其可药用盐、异构体、药物组合物和用途 | |
CN114507221B (zh) | 一种三嗪类化合物及其在制备抗病毒药物上的用途 | |
CN114790198B (zh) | 一种三嗪类化合物及其制备方法和应用 | |
US20230105838A1 (en) | Method of Treating COVID-19 | |
CN114933594A (zh) | 一种氟代三嗪类化合物、药物组合物及用途 | |
CN114805316B (zh) | 二酮氮杂环化合物或其可药用的盐、互变异构体及其制备方法、药物组合物及应用 | |
CN111233929B (zh) | 一种核苷类似物的氘代物及其制备方法和用途 | |
CN116751164A (zh) | 蛋白酶抑制剂、其制备和用途 | |
CN113321694A (zh) | N4-羟基胞苷衍生物及其制备方法和用途 | |
WO2024037520A1 (zh) | 一种酰胺类化合物及其制备方法、药物组合物和用途 | |
CN113620929A (zh) | 醛基类化合物及其制备方法、药物组合物和用途 | |
CN115490681A (zh) | 三嗪衍生物 | |
CN114181258B (zh) | 用于抗病毒治疗的核苷类化合物及用途 | |
CN115109042B (zh) | 三嗪类化合物或其可药用的盐、药物组合物和用途 | |
CN118434728A (zh) | 用于预防和治疗冠状病毒感染的化合物及其偶联物和方法 | |
CN115819423A (zh) | 一种瑞德西韦或其中间体的protac化合物及其制备方法与抗ev71的应用 | |
CN115385984B (zh) | 一种拟肽类衍生物、制备方法和应用 | |
CN112771048B (zh) | 流感病毒复制抑制剂及其中间体和用途 | |
CN116120282B (zh) | 具有ev71和/或cva16病毒抑制活性的化合物及其应用 | |
CN116041324A (zh) | 一种氘代吡唑二氯苯甲酰胺类化合物、药物组合物和用途 | |
CN113754594A (zh) | 喹唑啉酮类化合物或其可药用的盐、异构体及其制备方法、药物组合物和用途 | |
CN111995649A (zh) | 一种蝶啶酮核苷酸类似物及其药物组合物、制备方法和医药用途 | |
CN116874471A (zh) | 一种氘代三嗪类化合物及其在抗病毒上的应用 | |
CN111777638A (zh) | 喹啉类化合物、其制备方法、药物组合物和用途 | |
KR20230024887A (ko) | 항바이러스성 1,3-디-옥소-인덴 화합물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20220527 |